Joseph Cheriyan
Cambridge University Hospitals NHS Foundation Trust · Cambridge Unversity Hospitals NHS Foundation Trust; Unversity of Cambridge · Cambridge University Hospitals
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
17
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
28
PubMed author-name match
Trials
Studies that name Joseph Cheriyan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:30 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06555757 · Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensationCambridge University Hospitals NHS Foundation Trust · recruiting · Heart Failure · principal investigator
- N/ANCT06427694 · Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up StudyCambridge University Hospitals NHS Foundation Trust · recruiting · Acute Coronary Syndromes · principal investigator
- N/ANCT06243029 · A Study to Assess Multidomain Endpoints of an ECG PatchAstraZeneca · completed · Acute Decompensated Heart Failure · principal investigator
- Ph2/Ph3NCT04393246 · mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and MechanismsCambridge University Hospitals NHS Foundation Trust · completed · COVID-19 · principal investigator
- Ph3NCT04352933 · PROLIFIC ChemoprophylaxisTrial (COVID-19)Cambridge University Hospitals NHS Foundation Trust · unknown · COVID-19 · principal investigator
- Ph2NCT04241601 · Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORYCambridge University Hospitals NHS Foundation Trust · completed · Acute Coronary Syndromes · principal investigator
- Ph2NCT03449251 · A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxinCambridge University Hospitals NHS Foundation Trust · active not recruiting · Cardiovascular Diseases, Type 2 Diabetes Mellitus · principal investigator
- N/ANCT03355027 · Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV DiseaseCambridge University Hospitals NHS Foundation Trust · unknown · Atherosclerosis, Cardiovascular Diseases · principal investigator
- N/ANCT03312712 · Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung InflammationCambridge University Hospitals NHS Foundation Trust · unknown · Lung Inflammation, Sarcoidosis · principal investigator
- N/ANCT03273972 · INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY VolunteersCambridge University Hospitals NHS Foundation Trust · completed · Atherosclerosis, Cardiovascular Diseases · principal investigator
- Ph1/Ph2NCT03113773 · Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary SyndromesCambridge University Hospitals NHS Foundation Trust · completed · Ischemic Heart Disease · principal investigator
- Ph1NCT03098680 · A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular SystemsCambridge University Hospitals NHS Foundation Trust · terminated · Drug-Related Side Effects and Adverse Reactions, Cardiovascular System Disease · principal investigator
- N/ANCT02987465 · Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.Cambridge University Hospitals NHS Foundation Trust · completed · Cardiovascular Diseases, Chronic Kidney Disease · principal investigator
- N/ANCT02931188 · The Effect of Anacetrapib on Vascular Function and Arterial StiffnessCambridge University Hospitals NHS Foundation Trust · completed · Atherosclerotic Cardiovascular Disease, Vascular Disease · principal investigator
- N/ANCT02129309 · Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery PressuresCambridge University Hospitals NHS Foundation Trust · completed · COPD, Pulmonary Hypertension · principal investigator
- Ph2NCT01541852 · Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.Cambridge University Hospitals NHS Foundation Trust · completed · Chronic Obstructive Pulmonary Disease · principal investigator
- N/ANCT01100385 · TomVasc - Vascular Effects of Tomato ExtractCambridge University Hospitals NHS Foundation Trust · completed · Ischemic Heart Disease, Transient Ischemic Attack, Stroke · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:30 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis.Circulation · 2012171 citationsRCR 5.4
- Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.Br J Clin Pharmacol · 2016147 citationsRCR 5.7
- Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.Neurology · 2009142 citationsRCR 4.5
- Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.JACC Cardiovasc Imaging · 2012135 citationsRCR 3.6
- Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.Am J Cardiovasc Drugs · 2019134 citationsRCR 6.2
- Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.Circulation · 201188 citationsRCR 2.4
- 82 citationsRCR 3.6
- Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans.Arterioscler Thromb Vasc Biol · 200574 citationsRCR 1.9
- 66 citationsRCR 4.4
- 63 citationsRCR 2.8